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Deregulation of p27 and Cyclin D1/D3 Control Over
Mitosis Is Associated with Unfavorable Prognosis in
Non-small Cell Lung Cancer, as Determined in 405
Operated Patients
William Sterlacci, MD,* Michael Fiegl, MD,† Wolfgang Hilbe, MD,† Herbert Jamnig, MD,‡
Wilhelm Oberaigner, MD,§ Thomas Schmid, MD, Florian Augustin, MD, Jutta Auberger, MD,¶
Ellen C. Obermann, MD,# and Alexandar Tzankov, MD#
Introduction: A large group of interacting molecular factors, in-
volved in epithelialmesenchymal transition, epidermal growth factor
receptor (EGFR) signaling, and G1 mitotic phase, are shown to play
an important role in cancerogenesis and progression of non-small
cell lung cancer (NSCLC). Since success concerning potential cor-
relations, structural and numeric gene aberrations, and biological
risk assessment of these molecular factors are still lacking, com-
bined analysis of a multitude of intertwined factors is currently a
promising approach.
Methods: Cyclins (D1, D2, D3, and E), p21, p27, EGFR, Snail,
E-cadherin, -catenin, phosphatidylinositol-3 kinase, phosphatase
and tensin homologue, phosphorylated Akt, and phosphorylated
signal transducer, and activator of transcription-3 were analyzed by
immunohistochemistry in 405 surgically resected NSCLC, using a
standardized tissue microarray platform. In addition, the gene status
of EGFR and cyclin D1 was examined by fluorescence in situ
hybridization. Extensive clinical data were acquired, enabling de-
tailed clinicopathologic correlation during a postoperative follow-up
period of up to 14 years.
Results: The protein overexpressions of nuclear p27, cyclin D1,
cyclin D3, E-cadherin, and EGFR as assessed by immunohistochem-
istry were all associated with a significant reduction in overall
survival time. In addition, cyclin D1 proved especially important,
being the only independent molecular tumor-related factor with
prognostic significance by multivariable analysis. In analogy to
EGFR, recurrent numeric gene aberrations, particularly high-level
amplifications, of cyclin D1 were obvious.
Conclusions: The results emphasize that deregulation of control-
ling factors of the early G1 phase is of significant oncogenic
relevance and may represent a potential treatment target in
NSCLC.
Key Words: Non-small cell lung cancer, Cyclin D1, p27, EGFR,
Epithelial–mesenchymal transition.
(J Thorac Oncol. 2010;5: 1325–1336)
The process of carcinoma progression to metastatic dis-ease involves conversion of epithelial tumor cells into
motile mesenchymal-like cells, which may then breach the
underlying basal membrane, enter blood vessels, and
spread to distant organs. This epithelial–mesenchymal
transition (EMT) is a central step in tumor metastasis and
has been associated with epidermal growth factor receptor
(EGFR) signaling.1 Expression of E-cadherin, a transmem-
brane glycoprotein localized mainly in adherent junctions
is thereby down-regulated, which is associated with loss of
cell– cell adherence.2 Down-regulation of E-cadherin is
considered as a critical step and an indicator for EMT, and
it can be achieved by transcriptional suppression mediated
by the transcription factors Snail, Slug, and Twist.3 In
cancer cells, activation of EGFR increases the abundance
of Snail, which accumulates in the nucleus and suppresses
the expression of E-cadherin.4 E-cadherin is associated
with a group of proteins called catenins (-, -, and
-catenin) and is directly bound to -catenin, which also
acts as a cytoplasmic signaling molecule when unbound.
Reduction in E-cadherin leads to increased amounts of
unbound -catenin, which translocate to the nucleus and
induce expression of cell cycle genes.
The EGFR pathway is often implicated as an impor-
tant mechanism in carcinogenesis of various organs, espe-
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cially in non-small cell lung cancer (NSCLC).5 It is known
to affect cancer cell proliferation, apoptosis, angiogenesis,
and metastatic spread.5 After ligand binding, an intracel-
lular tyrosine kinase domain of EGFR is autophosphory-
lated, activating several downstream signaling pathways,
including signal transducer and activator of transcription
(STAT) and phosphatidylinositol-3 kinase (PI3K). Of the
seven known members of the STAT family, especially
STAT3 has been shown to be activated in many malignan-
cies.6 STATs have been described as playing an important
role in hematologic neoplasms, and increasingly in solid
cancers, such as those of prostate, pancreas, breast, and
head and neck.7,8 Activated STAT3 has also been implied
as a marker of poor prognosis in some tumors.9
PI3K, which is recruited by activated growth recep-
tor tyrosine kinases, such as EGFR, undergoes allosteric
activation of its catalytic subunit and then phosphorylates
phosphatidylinositol-4,5-bisphosphate (PIP2) on the intra-
cellular plasma membrane, generating phosphatidylinosi-
tol-3,4,5-trisphosphate (PIP3). Then, Akt translocates and
interacts with PIP3, resulting in tyrosine phosphorylation
of Akt. Thereby activated Akt (pAkt) then phosphorylates
several cellular proteins and may enter the nucleus, facil-
itating cell survival, cell growth, and cell cycle entry.10
Among other events, the degradation of the cytoplasmic
signaling molecule -catenin is inhibited, which then
translocates to the nucleus and combines with transcription
factors, causing expression of genes such as cyclin D1
(CCND1).11 pAkt phosphorylates, p21, inhibit its antipro-
liferative effects as a cylin-dependent kinase (CKD) inhib-
itor (CKI) by retaining it in the cytoplasm, which has also
been described for p27, another CKI of the same family
(kinase-inhibitory protein/CDK-inhibitory protein [KIP/
CIP]).11 In addition, pAkt has been identified as an inde-
pendent prognostic factor associated with decreased sur-
vival.12 Phosphatase and tensin homologue (PTEN)
negatively regulates PI3K-induced signaling by converting
PIP3 back to PIP2, thus acting as a tumor suppressor.
Merely part of the downstream signaling pathways of
EGFR is described here, which already becomes very
complex and intertwined (Figure 1). One can readily ap-
preciate the difficulty in targeted pharmacologic therapies,
considering the variety of evasion possibilities. It becomes
clear that EGFR with its multiple downstream components
involved in various signaling pathways plays a central role
in tumorigenesis. The different mechanisms of deregula-
tion, including gene mutations and amplifications, provide
tumor cells with a constantly activated pathway. Most of
the numerous existing reports involving EGFR pathways
deal with a single, or few downstream molecules. A likely
key to gain further insight here is to analyze a more
extensive portion of the complex EGFR signaling mecha-
nisms. To obtain significant correlations and improve bi-
ologic risk assessment, we considered EGFR-signaling
related factors associated with EMT and with control over
the G1 cell cycle-phase in NSCLC. The aim of this study
was to establish markers (or marker panels) in routine
histologic analysis, which might enable the pathologist a
clinically relevant prognostic grouping.
PATIENTS AND METHODS
Patients
The archival samples derived from 405 lung cancer
patients radically operated between 1992 and 2004 and
diagnosed with NSCLC at the Institute for Pathology,
Medical University of Innsbruck. Cases were selected only
based on tissue preservation. Hematoxylin and eosin
(H&E) stains from all available slides (complete tumor
sample) of all cases were reclassified by two pathologists
(W.S. and A.T.) without the knowledge of patient infor-
mation, according to the current World Health Organiza-
tion (WHO) classification of tumors of the lung as de-
scribed previously.13,14 Categories included squamous cell
carcinoma (SCC), adenocarcinoma (ACA), large cell car-
cinoma (LCC), adenosquamous carcinoma, sarcomatoid
carcinoma (which were all of the pleomorphic type), and
mucoepidermoid carcinoma. Cases containing less than
10% spindle cells or giant cells were noted as such, but
classified according to the major histologic component
present, as required by the WHO.13 All cases were exam-
ined immunohistochemically concerning neuroendocrine
differentiation as previously described.14 Thus, in addition
to classic LCC, a group of LCC with neuroendocrine
differentiation arised (LCNEC), according to the current
requirements of the WHO.13 Carcinoids were not included.
Tumor differentiation was graded as well, moderate, or
poor. The clinical information was documented within the
Twelve Years Retrospective of Lung Cancer survey, a
project aiming at analyzing various features of a large
number of lung cancer patients. These patients mainly
originated from the Austrian county of Tyrol and were all
diagnosed and treated at the Medical University Hospital
FIGURE 1. Signaling pathways of the epidermal growth
factor receptor. EGFR, epidermal growth factor receptor;
EMT, epithelial–mesenchymal transition; pAkt, phosphory-
lated Akt; PTEN, phosphatase and tensin homologue;
pSTAT3, phosphorylated signal transducer and activator of
transcription 3; PI3K, phosphatidylinositol-3 kinase; -cat,
-catenin; E-cad, E-cadherin; PIP2, phosphatidylinositol-
4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-
trisphosphate; EMT, epithelial–mesenchymal transition;
CCND1, cyclin D1 gene.
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of Innsbruck and associated hospitals. Approval for data
acquisition and analysis was obtained from the Medical
University of Innsbruck Ethics Committee (the local Insti-
tutional Review Board). The basic patients’ characteristics
including symptoms at presentation, smoking habits, co-
morbidities, and laboratory parameters, as well as the
complete course of treatment modalities, including surgery
and all lines of chemo- and radiotherapy, was document-
ed.15 Regarding therapy modalities, the patients were rou-
tinely discussed at the Medical University of Innsbruck
Tumor Board, and a state of the art recommendation of
therapy adapted to the condition of the patient was given.
Accordingly, there was a continuous shift of therapy mo-
dalities routinely applied in this comparably large interval
of patients recruited to the survey.15,16
Tissue Microarray Construction
Tumor material consisted of paraffin-embedded tissue
after fixation in 10% neutral buffered formalin. The tissue
microarray (TMA) was constructed as previously described.14
Briefly, representative tumor areas were marked on H&E
stained slides and four cylindrical 0.6-mm tissue cores each
were arrayed from the corresponding paraffin blocks into a
recipient block, using an arraying machine from Beecher
Instruments. The core coordinates were recorded for exact
location using Microsoft Excel and printouts assisted the
subsequent immunohistochemical evaluation. Four-microme-
ter-thick paraffin sections were cut. The first sections were
stained with H&E to confirm validity, and the other sections
were used for immunohistochemistry. Adhesive transfer tape
was not used.
Immunohistochemistry
Immunohistochemistry was performed using the auto-
mated staining systems, Ventana Benchmark XT and Nexes
received from Ventana Medical Systems Inc. (Tucson, AZ),
except for pSTAT3, cyclin D2 and D3, cyclin E, p21 and p27
stainings, which were incubated overnight at 4°C and stained
using the ABC method. The primary antibodies used and
their dilutions are listed in Table 1.
Immunohistochemical Evaluation
Only spots containing at least 20 vital tumor cells were
evaluated. If all four spots of a case did not meet this criterion
it was excluded. Tumor cells were counted independently by
two pathologists (W.S. and A.T.) to study agreement between
the observers and the percentage of positive cells, staining
localization was also noted for each spot, followed by the
calculation of the arithmetic mean value. The only exception
was the evaluation of EGFR staining, which was scored
according to the EGFR pharmDx Interpretation Manual by
Dako (Glostrup, Denmark). EGFR-negative (0): absence of
membrane staining above background in all tumor cells;
EGFR-positive (staining intensity: 1, 2, or 3): any
staining of tumor cell membranes above background level,
whether complete or incomplete circumferential staining.
CCND1 Fluorescence In Situ Hybridization
The CCND1 gene status was assessed independently by
two pathologists (E.O. and A.T.) by fluorescence in situ
hybridization (FISH) using dual-color, break-apart probes
(from Vysis/Abbott, Downers Grove, IL; CCND1: order no.
05J96-001) on paraffin-embedded tissue sections according
to the protocol published by Vysis/Abbott (www.abbottmolecular.
com). Slides were counterstained with 125 ng/ml of 4,6-
diamino-2-phenylindole in antifade solution. FISH signals
were scored with a Zeiss fluorescence microscope equipped
with double-band pass filters for simultaneous visualization
of Spectrum Green and Spectrum Orange signals. Cases on
the TMA were considered evaluable for FISH if at least 200
tumor cell nuclei per core displayed positive signals. Splits
were recorded as percentage of cells bearing an abnormality
of all the analyzed cells. The cutoff score to consider a case
rearranged was the mean plus 3SDs of split nuclei in the
reference cases (i.e., 9%). The minimal distance of split
signals was defined as at least three single-signal widths.
High-level amplification was defined as presence of either
more than 10 gene signals or tight clusters of at least five gene
signals. Polysomies and low-level amplifications of CCND1
(termed together “gains”) were defined as presence of tumor
cell nuclei with three or more signals exceeding the mean
plus 3SDs of tri-/polysome nuclei in reference normal lung
parenchyme (i.e., 10% tumor cells with 3 fused signals).
EGFR Fluorescence In Situ Hybridization
The EGFR gene status was assessed independently by
two pathologists (E.O. and A.T.) by FISH using dual-color
TABLE 1. Applied Antibody Panel
Antibody Source Dilution Retrieval
EGFR Ventana 790–2988 Prediluted Protease 1 12
pAkt Abcam ab8932 1:450 Citrate pH 6, autoclave
120°C 5
PTEN Novocastra
NCL-PTEN
1:200 CC1
Snail Abgest AP2054a 1:50 ER2 pH 9, microwave
100°C 20
-Catenin Ventana 760–4242 Prediluted CC1
E-cadherin DAKO IRO59 Prediluted Citrate pH 6, microwave
80°C 30
PI3K BD Bioscience
610046
1:1000 ER2 pH 9, microwave
100°C 20
pSTAT3 Cell Signaling 9145 1:50 TEC pH 9, microwave
100°C 30
Cyclin D1 DCS CI677C01 1:50 Citrate pH 6, microwave
100°C 30
Cyclin D2 Santa Cruz sc-181 1:8000 Citrate pH 6, microwave
98°C 60
Cyclin D3 Novocastra
NCL-Cyclin D3
1:80 Citrate pH 6, microwave
98°C 60
Cyclin E Neomarkers
MS-1060-S
1:20 Citrate pH 6, microwave
98°C 60
p27 Neomarkers
MS-256
1:250 Citrate pH 6, microwave
98°C 60
p21 Thermo MS-387-P 1:400 Citrate pH 6, microwave
98°C 60
EGFR, epidermal growth factor receptor; pAkt, phosphorylated Akt; PTEN, phos-
phatase and tensin homologue; pSTAT3, phosphorylated signal transducer and activator
of transcription 3; PI3K, phosphatidylinositol-3 kinase.
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probes (LSI 7p12 EGFR spectrum orange and CEP7 7p11.1-
q11.1 spectrum green from Vysis/Abbott; order no. 05J48-
001) to the protocol published by Vysis/Abbott (www.
abbottmolecular.com). Patients were classified into five FISH
strata with ascending number of copies of the EGFR gene per
cell according to Cappuzzo’s criteria: (1) disome (2 copies
in 90% of cells), (2) low-grade amplified (2 copies in
40% of cells, three copies in 10% of the cells, 4 copies
in 10% of cells), (3) low polysome (4 copies in 10–40%
of cells), (4) high polysome (4 copies in 40% of cells),
and (5) amplified cases (defined by presence of tight EGFR
gene clusters and a ratio of EGFR gene to chromosome of2
or 15 copies of EGFR per cell in 10% of analyzed
cells).17
Statistical Analysis
The degree of agreement between observers was eval-
uated by interclass correlation coefficients, using reliability
Cronbach’s alpha analysis. Multivariable analysis of clinico-
pathological and immunohistochemical parameters was per-
formed using the Spearman test corrected for multiple testing,
considering p less than 0.0031 as significant. In addition, for
the three major histology types (ACA, SCC, and LCC), the
mean percentage of positively stained cells was compared,
and significant markers (p [ANOVA] 0.005) were further
analyzed using the Kruskall-Wallis-H test. The prognostic
relevance of respective markers was assessed by means of
receiver operating characteristic analysis, selecting death as
the state variable. Optimal cutoff values were calculated
using the Youden index (J) for variables demonstrating an
asymptomatic significance less than 0.2 and an adequately
shaped receiver operating characteristic curve, otherwise the
median was selected.18 Kaplan-Meier curves were calculated
for survival estimates, and a log-rank statistic was used to
determine differences between groups. Survival estimates for
dual combinations of markers were analyzed together as:
either markers negative, any one marker positive, or both
markers positive. All parameters with at least 10 deaths and
a p less than 0.1 for overall survival estimates by the Kaplan-
Meier method were analyzed by the multivariable Cox re-
gression model. The value of p less than 0.05 was considered
as significant. Two-sided tests were used throughout. Statis-
tical calculations were performed using SPSS 17.0 software
(SPSS, Chicago, IL).
RESULTS
Histopathology and Patient Characteristics
The tumor samples were derived from 405 radically
operated patients. After revision of all 405 cases, 207 were
diagnosed with ACA, 126 SCC, 58 LCC (including 16
LCNEC) nine adenosquamous carcinoma, four pleomorphic,
and one mucoepidermoid carcinoma. Distribution of patho-
logic tumor stage by Union Internationale Contre le Cancer
(UICC) revealed 196 stage I, 61 stage II, 54 stage IIIA, 19
stage IIIB, and 14 stage IV. For 61 patients, the definite tumor
stage was not feasible. The patient population comprised 290
men and 115 women with an average age of 62 years and a
range from 23 to 84 years (Table 2).
Immunohistochemistry
Cronbach’s alpha for interobserver reproducibility of
the immunohistochemical markers was excellent (at least
0.87 for PTEN). Positive staining for cyclin D1, cyclin D2,
cyclin D3, cyclin E, p21, pSTAT3, Snail, and PTEN was
observed exclusively nuclear (Figure 2A–E, H, N, P). Along
with an unequivocal nuclear signal, pAkt demonstrated addi-
tional cytoplasmic staining in some cases, which was ex-
tremely faint and not taken into account for further analysis
TABLE 2. Clinicopathological Characteristics
Characteristic
No. of Patients
(N  405) %
Age (yr)
Median (range) 62 (23–84)
64 218 53.8
64 187 46.2
Gender
Male 292 72.1
Female 113 27.9
pUICC stage
I 203 50.1
II 61 15.1
IIIA 54 13.3
IIIB 19 4.7
IV 14 3.5
Unknown 54 13.3
Histology
Adenocarcinoma 207 51.1
Squamous cell carcinoma 126 31.1
Large cell carcinoma 56 13.8
Others 16 4
Sarcomatoid component
None 390 96.3
10% 11 2.7
10% 4 1
Differentiation
Well 21 5.2
Moderate 170 42
Poor 214 52.8
T stage
1 132 32.6
2 187 46.2
3 27 6.6
4 17 4.2
Unknown 42 10.4
N stage
0 195 48.2
1 86 21.2
2 43 10.6
Unknown 81 20
Smoking status
Never smoker 15 3.7
Smoker 181 44.7
Unknown 209 51.6
pUICC, pathological Union Internationale Contre le Cancer.
Sterlacci et al. Journal of Thoracic Oncology • Volume 5, Number 9, September 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1328
(Figure 2I). EGFR demonstrated a complete or incomplete
membranous pattern, along with a fainter-stained cytoplasm
(Figure 2M). E-cadherin demonstrated a mostly incomplete
membranous pattern with a fainter-stained cytoplasm and
PI3K stained the cytoplasm with a membranous accentuation
(Figure 2L, O). The staining localization for p27 was ob-
served in the nucleus as well as in the cytoplasm, often
concomitant (Figure 2F, G). Both patterns were recorded
separately. Considering -catenin, two staining patterns were
also observed: a membranous and a nuclear signal (Figure 2J,
K). Because the membranous -catenin staining pattern was
absent only in a single case, it was excluded from further
analysis. Quantitative immunohistochemical data are shown
in Table 3.
FISH Analysis
EGFR FISH was successful in 210 cases, whereas
CCND1 FISH succeeded only in 160 cases. Cronbach’s alpha
for interobserver reproducibility of FISH analyses was excel-
lent (0.95 for EGFR and 0.98 for CCND1). The respective
EGFR status is shown in Table 4 and Figure 3A. Twelve of 54
SCC, nine of 76 ACA, and six of 26 LCC (including 3/5
LCNEC) showed high-level amplifications of the CCND1
gene, whereas nine of the 54, 19 of the 76, and three of the 26
(1/5 LCNEC) showed low-level gains, respectively (Figure
3B). Two cases, one SCC and one LCC each, showed split
red and green signals corresponding to CCND1 gene rear-
rangements; in the case of SCC, the number of free red
(telomeric) signals significantly exceeding that of the green
(centromeric) ones, suggesting an unbalanced translocation
with double minutes (Figure 3C). A “gene dosage effect” was
highly likely, because cases (n100) without numeric alter-
ations of the CCND1 gene expressed cylcin D1 in a mean of
7.5  12.4% of cells, whereas cases with low-level gains
(n 31) expressed cyclin D1 in 15.5 19.4% and those with
high-level amplifications (n  28) expressed cyclin D1 in
31.6 23.7% of tumor cells (p 0.001). Immunohistochem-
ical expression of EGFR protein increased with increasing
gene copy number by FISH (rho  0.255) and cyclin D1
expression correlated with CCND1 gene copy number by
FISH (rho  0.477).
Correlations Between Variables
The results of the correlation analysis are demonstrated
in Tables 5 and 6. The strongest correlation was found
between cytoplasmic and nuclear expression of p27. Impor-
FIGURE 2. Immunohistochemical expression of
cyclin D1 (A), cyclin D2 (B), cyclin D3 (C), cyclin E
(D), p21 (E), nuclear p27 (F), cytoplasmic p27
(G), phosphorylated signal transducer and activa-
tor of transcription 3 (H), phosphorylated Akt (I),
membranous -catenin (J), nuclear -catenin (K),
E-cadherin (L), epidermal growth factor receptor
(M), Snail (N), phosphatidylinositol-3 kinase (O),
and phosphatase and tensin homologue (P) in
non-small cell lung cancer tissue microarray sam-
ples. Original magnification 400.
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tantly, cyclins (D1, D2, D3, and E) were associated with
CKIs (p21 and p27). Furthermore, EGFR gains and overex-
pression were determined by FISH and immunohistochemis-
try, respectively, significantly cohered to SCC when com-
pared with other histologic types (p  0.004 and p  0.001,
respectively). Accordingly, ACA demonstrated a negative
correlation with EGFR expression (p 0.001). T and N stage
did not show significant correlations with the examined
biomarkers.
Survival Analysis
All results for calculations of survival estimates are
shown in Table 7. Male gender, age 64 years, pUICC 
I, T stage 1, N stage 0, and sarcomatoid carcinoma
were associated with a significantly worse overall survival
time, as well as patients expressing E-cadherin, nuclear
p27, or cyclin D3 above respective cutoff levels (Figure
4A–C). Cyclin D1 was not a significant parameter by
univariable analysis (Figure 4D). When EGFR immuno-
histochemistry results were categorized as either positive
(scores 1) or negative (score  0), a significantly de-
creased overall survival time was noted for EGFR positive
cases (Figure 4E). When analyzed stratified according to
the major histologic subtypes, SCC, ACA and LCC, all
subgroups still demonstrated a worse overall survival time
when the above-mentioned markers were positive, al-
though statistical significance was only achieved for the
group of ACA (nuclear p27: p  0.047, E-cadherin: p 
0.017, EGFR expression: p  0.04). When stratified with
respect to pUICC stages I and  I, p values did not reach
statistical significance. A further reduction in overall sur-
vival time was noted for dual combinations of any of the
markers EGFR, cyclin D1, cyclin D3, nuclear p27, and
E-cadherin (all p  0.03) (Figure 4F). All the combina-
tions again only achieved statistical significance in the
group of ACA, when analyzed stratified according to the
major histologic subtype. When analyzed according to
stage, the combination of E-cadherin and EGFR expres-
sion was associated with a significantly reduced overall
TABLE 3. Immunohistochemical Expression Profiles
Parameter
Evaluable
Cases
Percentage of Stained Cells
Cases Above
Cutoff (%)Median Mean Range Cutoff
p27 Nuclear 382 20 30.2 0–100 45 111 (29.1)
p27 Cytoplasmic 381 20 33.4 0–100 20 225 (59.1)
p21 383 16.7 23.9 0–95 16 194 (50.7)
Cyclin D1 390 5 11.9 0–100 15 100 (25.6)
Cyclin D2 265 0 4.3 0–70 0 109 (41.1)
Cyclin D3 391 2 7.5 0–90 3.5 167 (42.7)
Cyclin E 389 0.66 6.1 0–80 0.66 193 (49.6)
PI3K 382 100 97.1 30–100 100 290 (75.9)
PTEN 379 0 8.4 0–100 0 57 (15)
pAkt 366 0 5.6 0–80 0 152 (41.5)
-Catenin
nuclear
391 0 0.95 0–80 0 10 (2.6)
E-cadherin 391 20 34.1 0–90 25 190 (48.6)
pSTAT3 384 0 1.3 0–36.6 0 56 (14.6)
Snail 376 0 0.27 0–10 0 27 (7.2)
EGFR 383 Score 0: 198 1: 60 0 185 (48.3)
2: 69 3: 56
PI3K, phosphatidyl-inositol-3 kinase; PTEN, Phosphatase and tensin homologue; pAkt, phosphorylated-Akt; pSTAT3,
phosphorylated signal transducer and activator of transcription 3; EGFR, epidermal growth factor receptor.
TABLE 4. EGFR FISH Analysis According to Histological Lung Cancer Type
FISH Status
Total
(N  210) ACA SCC LCC PLM ASC MEC
Disome/diploid 53 (25.2) 26 (30.6) 17 (21.5) 10 (27.1) 0 0 0
Low-grade amplified 14 (6.7) 8 (9.4) 4 (5.1) 1 (2.7) 0 1 (16.7) 0
Amplified 16 (7.6) 4 (4.7) 11 (13.9) 0 0 1 (16.7) 0
Low polysomy/polyploidy 115 (54.8) 43 (50.6) 39 (49.4) 26 (70.2) 2 (100) 4 (66.6) 1 (100)
High polysomy/polyploidy 12 (5.7) 4 (4.7) 8 (10.1) 0 0 0 0
Data are expressed as N (%).
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; ACA, adenocarcinoma; SCC, squamous
cell carcinoma; LCC, large cell carcinoma; PLM, pleomorphic carcinoma; ASC, adenosquamous carcinoma; MEC, mucoepi-
dermoid carcinoma.
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survival time for pUICC stage  I (p  0.035). Of all
immunohistochemical parameters examined by multivari-
able analysis, cyclin D1 was identified as the only inde-
pendent tumor-related marker indicating poor overall sur-
vival time (Table 8). When stratified according to major
histologic subtype, multivariable analysis revealed cyclin
D1 as the only significant marker indicating worse survival
for SCC (relative risk: 2.912, 95% confidence interval
[CI]: 1.399–6.064, p  0.004) and respectively age for
LCC (relative risk: 3.779, 95% CI: 1.484–9.621, p 
FIGURE 3. Fluorescence in situ hybridization analysis for
epidermal growth factor receptor (EGFR) (A) and Cyclin D1
(CCND1) genes (B, C). (A) Note highly increased numbers of
red (EGFR) compared with green signals (centromere 7) cor-
responding to high-level amplification. (B) Note increased,
but balanced red (telomeric) and green (centromeric) signals
in tumor cells, due to amplification of doubled-colored
probes flanking CCND1, corresponding to high amplification
of CCND1. (C) Note split red (telomeric) and green signals
(centromeric) as well as increased red signals corresponding
to unbalanced translocation involving the CCND1 locus on
chromosome 11 with double minutes of the telomeric parts
of the chromosome.
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0.005). For ACA, N stage (relative risk: 9.501, 95% CI:
2.695–33.488, p  0.001), pUICC (relative risk: 0.246,
95% CI: 0.7–0.863, p  0.029), T stage (relative risk:
1.729, 95% CI: 1.045–2.862, p  0.033), and cyclin D3
(relative risk: 1.729, 95% CI: 1.040–7.824, p  0.035)
were significantly associated with decreased overall sur-
vival. Markers implicated in the process of EMT such as
-catenin and Snail clearly played a subordinate role. The
impact of E-cadherin also became inferior when analyzed
by multivariable testing.
DISCUSSION
This study analyzes a large and intertwined group of
interacting molecular factors, involving EGFR signaling,
EMT, and G1 mitotic phase, which play an important role
in cancerogenesis and progression of NSCLC. Numerous
reports involving a single or only a few of the mentioned
molecular markers exist, but success concerning potential
correlations, structural and numeric gene aberrations of the
respective genes and biologic risk assessment is still lack-
ing. It has been stated that analysis of multiple markers is
most likely superior to any single marker for the prediction
of clinical outcome in NSCLC.19 A reasonable and com-
prehensible approach is to investigate the impact of dif-
ferent factors known to be involved with one and another.
In addition to a multitude of interlinked molecular factors,
this study has the advantage of a large patient group with
extensive clinical data available, and a follow-up period of
up to 14.5 years after surgical tumor resection (median
overall postoperative survival: 3.2 years). By applying a
standardized TMA platform, an ideal method of evaluation
was provided.20
Expressions of nuclear p27, cyclin D1, cyclin D3,
E-cadherin, and EGFR were all identified as having a signif-
icant impact on overall survival time in NSCLC in curatively
operated patients. Increased positive staining results for these
factors were associated with a significant reduction in overall
survival time. Reduced overall survival time was still obvious
when the patient cohort was stratified according to histologic
tumor subtype, but always only statistically significant for the
group of ACA.
Among the CKIs, p27 regulates transition of the cell
cycle from the G1 to the S phase by its activity as a potent
inhibitor of cyclins complexed with CDK.21 Because p27
must be localized to the nucleus to function as a CKI,
mechanisms resulting in proteosomal degradation, nuclear
export, or cytoplasmic retention will limit its activity and
promote G1-S progression. Nuclear and cytoplasmic staining
of p27 demonstrated a strong correlation with each other in
this study, indicating a deregulation of p27, appreciable by its
cytoplasmic localization. Reduced levels of p27 are frequent
in human breast and colon cancers and have been associated
with poor prognosis,22–24 which has also been reported for
NSCLC.25 On the other hand, especially studies involving
lymphomas have demonstrated that highly malignant neopla-
sias may also be associated with increased nuclear staining of
p27.26,27 An explanation for this somewhat controversial
finding is the association with increased expression of cyc-
lins, causing nuclear sequestration of p27.26 This suggests
that p27 protein in these cases is rendered nonfunctional as an
inhibitor of cell-cycle progression. Indeed, our results also
demonstrate a significant correlation between increasing nu-
clear p27 expression and increased cyclin D1, cyclin D3, and
cyclin E. In addition, these cyclins were also significantly
associated with increased expression of p21, another CKI of
the same molecular family (CIP/KIP) as p27. Our results
emphasize that the interpretation of immunohistochemical
staining of p27 is not always straight forward. An increased
nuclear staining result is not proof of normally functioning
p27, but may indicate an abnormal sequestration of p27
protein. A similar scenario is often described for p16 in
cervical squamous carcinoma.28 p16, a CKI of the INK4/ARF
family, whose overexpression has repeatedly been reported to
be typical of dysplastic and neoplastic epithelium of the
cervix, slows down the cell cycle by inactivating the CDK
that phosphorylates the tumor suppressor retinoblastoma pro-
tein (pRb).29 In analogy, p16 overexpression in cervical
lesions is hypothesized to be caused by the functional inac-
tivation of Rb.30
Loss of E-cadherin has often been reported in associa-
tion with tumor progression31–33 and poor prognosis.34 Our
results show a reduction in E-cadherin expression in every
TABLE 6. Correlations Between Immunohistochemical Parameters and Histological
Tumor Type
Parameter
Mean Percentage of Stained Cells (SD)
p (Kruskall-Wallis-H)Adenocarcinoma
Squamous Cell
Carcinoma
Large Cell
Carcinoma
pSTAT3 1.9 (5.4) 0.5 (2.9) 0.4 (1.9) 0.001
Nuclear p27 33.7 (29.1) 22.3 (22.9) 38.4 (24.7) 0.001
Cytoplasmic p27 42.6 (33.8) 19.7 (21.3) 34.3 (29.6) 0.001
p21 20.4 (21.5) 32.1 (22.8) 20.1 (21.5) 0.001
E-cadherin 43.9 (32.9) 21.5 (25.4) 26.8 (29.9) 0.001
Cyclin D1 11.8 (17.7) 11.8 (16.6) 13.2 (19.5) 0.862
EGFR (IHC) 0.7 (1.1)a 1.4 (1.2)a 0.6 (0.9)a 0.001
a Results indicate mean score (SD).
pSTAT3, phosphorylated signal transducer and activator of transcription 3; EGFR, epidermal growth factor receptor; IHC,
immunohistochemistry.
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evaluable NSCLC case. Nearly half (45.5%) the cases con-
tained only up to 10% positively stained tumor cells, and not
in a single case stained more than 90% of the tumor cells.
Other reports have even considered more than 90% of stained
tumor cells as the cutoff level for a positive E-cadherin
status.35 Loss of E-cadherin correlated with loss of differen-
tiation in our study, a finding well in line with other reports.36
After establishing a prognostically relevant cutoff level, our
series demonstrated a significantly reduced overall survival
time for patients with E-cadherin positive tumors. For a
reliable interpretation of this finding, the staining pattern
plays an important role. Analysis of the staining results
revealed a mostly incomplete membranous pattern of the
tumor cells with additional invariable staining of the cyto-
plasm. This is in contrast to the expected complete, exclu-
sively membranous pattern in normal tissue.35 Cytoplasmic
localization of E-cadherin has been attributed to loss of
normally functioning membranous E-cadherin with subse-
quent cytoplasmic accumulation.32 This underlines the im-
portance of precise analysis of staining results for accurate
interpretation. In our series, all cases demonstrated a reduced
level of E-cadherin expression and an abnormal staining
TABLE 7. Postoperative Overall Survival Analysis by Kaplan-
Meier Estimates According to Clinicopathological and
Immunohistochemical Parameters
Variables
No. of
Patients
Median
Postoperative
OS (mo) p
Gender
Male 292 37.8 0.012
Female 113 74.8
Age
64 218 66.8 0.003
64 187 37.8
Histology
Adenocarcinoma 207 45.4 0.361
Squamous cell carcinoma 126 49.6
Large cell carcinoma 58 31.5
Sarcomatoid
10% 401 45 <0.001
10% 4 9.1
T stage
T1 132 74.8 0.02
T2–4 231 40.1
N stage
N0 195 83.8 <0.001
N1–2 129 28.3
pUICC
I 203 75.9 <0.001
II–IV 148 31
Smoker status
Never smoker 15 65 0.941
Smoker 181 46.5
p27 Nuclear
Below cutoff 271 46.6 0.019
Above cutoff 111 35
p27 Cytoplasmic
Below cutoff 156 42.1 0.58
Above cutoff 225 45
p21
Below cutoff 189 40.7 0.537
Above cutoff 194 47.7
Cyclin D1 (IHC)
Below cutoff 290 47.4 0.07
Above cutoff 100 39.1
Cyclin D2
Below cutoff 156 43.8 0.725
Above cutoff 109 41.7
Cyclin D3
Below cutoff 224 47.7 0.019
Above cutoff 167 44
Cyclin E
Below cutoff 196 45.4 0.442
Above cutoff 193 44.7
Cyclin D1 (FISH)
Negative 132 44 0.536
High-level gains 19 35
Variables
No. of
Patients
Median
Postoperative
OS (mo) p
PI3K
Below cutoff 92 36.8 0.307
Above cutoff 290 46.4
PTEN
Below cutoff 322 44.5 0.787
Above cutoff 57 46.5
pAkt
Below cutoff 214 45.4 0.598
Above cutoff 152 42.9
EGFR (IHC)
Negative 198 58.9 0.027
Positive 185 36.2
EGFR (FISH)
Negative 182 47.6 0.205
High polysomy or amplification 28 36.8
Beta-catenin nuclear
Below cutoff 381 45.4 0.232
Above cutoff 10 15.4
E-cadherin
Below cutoff 201 59.5 0.026
Above cutoff 190 36.2
pSTAT3
Below cutoff 328 44.7 0.776
Above cutoff 56 48.2
Snail
Below cutoff 349 45 0.552
Above cutoff 27 82.4
PI3K, phosphatidyl-inositol-3 kinase; PTEN, phosphatase and tensin homologue;
pAkt, phosphorylated-Akt; pSTAT3, phosphorylated signal transducer and activator of
transcription 3; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry;
FISH, fluorescence in situ hybridization; pUICC, pathological Union Internationale
Contre le Cancer.
Bold text indicates statistically significant P values.
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pattern, indicating a deregulation of E-cadherin. Therefore,
tumors above the calculated cutoff value in our cohort (higher
percentage of abnormally stained cells) most likely represent
tumors with a more advanced stage in deregulation of E-
cadherin.
EGFR expressing cases were associated with a sig-
nificantly decreased overall survival time when compared
with EGFR negative cases, which has been widely reported.37
Significantly increased EGFR gene copy number (amplifica-
tion or high polysomy/-ploidy) was accompanied by worse
overall survival time, although without reaching statistical
significance. A positive correlation between EGFR expres-
sion and EGFR FISH status was obvious. This supports
previous reports stating that overexpression of EGFR by
immunohistochemistry is associated with increased EGFR
gene copy numbers by FISH analysis.38 Also in line with
most other studies is the association between EGFR expres-
sion and SCC, although contradictory results have been
reported.39 Interestingly, cases positive for any dual combi-
nation of the immunohistochemical markers, nuclear p27,
cyclin D1, or cyclin D3 with EGFR, were all associated with
a further decrease in overall survival time.
At multivariable analysis, cyclin D1 was identified as
the only independent marker indicating poor overall sur-
vival time in our cohort. Although reports concerning
cyclin D1 in NSCLC offer divergent conclusions, our
finding is well in line with most others, especially recently
published studies.40 Cyclin D1 is often both amplified and
overexpressed in NSCLC and preinvasive bronchial le-
sions. Marchetti et al.41 found that 32% of their lung
cancer cohort (N  57) demonstrated increased gene copy
numbers of CCND1 and 44% were positive immunohisto-
chemically. Betticher et al.42 reported similar results (15%
and 47%, respectively, N  53). The discrepancy can be
explained by the amount of gene copies that were required
for considering CCND1 as amplified (twofold for the
former and threefold for the latter group). The results of
our comparably large series support and considerably ex-
tend these findings, because altogether more than 35% of
FIGURE 4. Kaplan-Meier survival estimate graphs comparing cases above and below cutoff levels for E-cadherin (A), nuclear
p27 (B), cyclin D3 (C), cyclin D1 (D), EGFR (E), and combination of E-cadherin and cyclin D3 (F).
TABLE 8. Multivariable Cox Proportional Hazard Analysis of
Overall Survival
Parameter
Relative
Risk 95% CI p
N stage (N0 vs. N0) 3.521 1.917–6.469 <0.001
Age, yr (64 vs. 64) 1.770 1.275–2.458 0.001
Cyclin D1 (below vs. above cut-off) 1.577 1.090–2.282 0.016
Female vs. male 1.420 0.980–2.58 0.064
pUICC stage (I vs. I) 0.625 0.344–1.142 0.127
E-cadherin (below vs. above cut-off) 1.208 0.878–1.662 0.245
T-stage (T1 vs. T1) 1.229 8.65–1.747 0.250
EGFR (IHC) (score 0 vs. 0) 1.197 0.864–1.657 0.279
Cyclin D3 (below vs. above cut-off) 1.153 0.810–1.642 0.430
p27 nuclear (below vs. above cut-off) 1.064 0.715–1.583 0.761
EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; pUICC,
pathological Union Internationale Contre le Cancer.
Bold text indicates statistically significant P values.
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NSCLC cases showed CCND1 gains (17.5% high-level
and 19.4% low-level gene amplifications, N  160). In
addition, the coincidence between CCND1 gene amplifi-
cation and increased cyclin D1 protein expression was
obvious, which has been found in NSCLC and other
tumors.43,44 Importantly, cyclin D1 expression has been
associated with EGFR-mutant lung cancer cells, which
proved to be sensitive to the cyclin-dependent kinase
inhibitor flavopiridol, confirming the functional relevance
of the cyclin D axis.45 Our data did not show significant
correlations between EGFR and cyclin D1, concerning
either gene levels or protein expression.
Our study puts special emphasis on the procedure of
EMT, related to EGFR signaling, by integrating a number
of molecules currently considered as playing an important
role herein. Other than poor survival associated with ab-
errant expression of E-cadherin, we could not demonstrate
any significant findings in this context. Sarcomatoid car-
cinomas did show a significant reduction in overall sur-
vival time compared with other histologic subtypes, but
the former group consisted of only four cases. In addition,
while two cases were in stage IB, the other two were in an
advanced stage (IIIA and IV). This small number of
sarcomatoid carcinomas does not allow meaningful con-
clusions; also, the advanced stage in half these cases is the
most likely explanation for the dismal outcome. It must be
stressed that although sarcomatoid carcinomas are likely
due to EMT, this is not essentially necessary. For further
support, molecular factors implicated in EMT were
taken into account, which largely proved irrelevant for
prognosis.
In conclusion, our study demonstrates the important
impact that deregulation of p27, cyclin D1, and D3 has for
the prognosis of NSCLC patients, indicating significantly
decreased overall survival time. Especially, cyclin D1
proved to be a valuable marker, being the only (of multi-
ple) independent molecular tumor-related factor with prog-
nostic significance. Age was proved to be an independent
parameter with prognostic significance indicating de-
creased overall survival by multivariable analysis. In con-
trast, the gender associated survival difference was still
obvious, but not significant by multivariable analysis.
When stratified according to age (64 versus 64 years),
survival analysis showed the same tendency as described
for the entire cohort. Notably, the only parameter here
associated with a lower p value in the subgroup analysis
was nuclear p27 expression for patients younger than 64
years (p  0.008). Analogous to the EGFR gene, the
recurrent numeric aberrations of the CCND1 gene in
NSCLC, especially in SCC and LCC, including LCNEC
emphasize its oncogenic relevance, which might also rep-
resent a potential treatment target in NSCLC. In operated
patients, staining for cyclin D1 might be a reasonable
additional analysis in routine diagnostics due to its prog-
nostic information. It will have to be established whether
this also holds true for NSCLC patients diagnosed in an
advanced, nonoperable stage. Even more importantly, the
value of prognostic markers should be tested both prospec-
tively and for their predictive value in terms of therapy
efficacy.
REFERENCES
1. Lo HW, Hsu SC, Xia W, et al. Epidermal growth factor receptor
cooperates with signal transducer and activator of transcription 3 to
induce epithelial-mesenchymal transition in cancer cells via up-regula-
tion of TWIST gene expression. Cancer Res 2007;67:9066–9076.
2. Lu Z, Ghosh S, Wang Z, et al. Downregulation of caveolin-1 function by
EGF leads to the loss of E-cadherin, increased transcriptional activity of
beta-catenin, and enhanced tumor cell invasion. Cancer Cell 2003;4:
499–515.
3. Cano A, Pe´rez-Moreno MA, Rodrigo I, et al. The transcription factor
snail controls epithelial-mesenchymal transitions by repressing E-cad-
herin expression. Nat Cell Biol 2000;2:76–83.
4. Lee MY, Chou CY, Tang MJ, et al. Epithelial-mesenchymal transition in
cervical cancer: correlation with tumor progression, epidermal growth
factor receptor overexpression, and snail up-regulation. Clin Cancer Res
2008;14:4743–4750.
5. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of
targeted inhibitors. Nat Rev Cancer 2005;5:341–354; erratum 580.
6. Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene
2000;19:2474–2488.
7. Meier C, Hoeller S, Bourgau C, et al. Recurrent numeric aberrations of
JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod
Pathol 2009;22:476–487.
8. Yu H, Jove R. The STATs of cancer—new molecular targets come of
age. Nat Rev Cancer 2004;4:97–105.
9. Kusaba T, Nakayama T, Yamazumi K, et al. Activation of STAT3 is a
marker of poor prognosis in human colorectal cancer. Oncol Rep
2006;15:1445–1451.
10. Engelman JA. The role of phosphoinositide 3-kinase pathway inhibitors
in the treatment of lung cancer. Clin Cancer Res 2007;13:4637–4640.
11. Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev 2004;30:193–204.
12. David O, Jett J, LeBeau H, et al. Phospho-Akt overexpression in
non-small cell lung cancer confers significant stage-independent survival
disadvantage. Clin Cancer Res 2004;10:6865–6871.
13. Travis W, Brambilla E, Mu¨ller-Hermelink H, et al. Pathology and
Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon:
IARC Press, 2004.
14. Sterlacci W, Fiegl M, Hilbe W, et al. Clinical relevance of neuroendo-
crine differentiation in non-small cell lung cancer assessed by immuno-
histochemistry: a retrospective study on 405 surgically resected cases.
Virchows Arch 2009;455:125–132.
15. Fiegl M, Hilbe W, Auberger J, et al. Twelve-year retrospective analysis
of lung cancer–the TYROL Study: daily routine in 1,424 patients
(1995–2006). J Clin Oncol 2008;20:19063.
16. Hilbe W, Aigner K, Dittrich C, et al. Expert recommendations 2006 on
the rationale for second-line therapy for non-small cell bronchial neo-
plasms. Wien Klin Wochenschr 2007;119:259–266.
17. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor
gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
J Natl Cancer Inst 2005;97:643–655.
18. Tzankov A, Zlobec I, Went P, et al. Prognostic immunophenotypic
biomarker studies in diffuse large B cell lymphoma with special empha-
sis on rational determination of cut-off scores. Leuk Lymphoma 2010;
51:199–212.
19. Yoo J, Jung JH, Lee MA, et al. Immunohistochemical analysis of
non-small cell lung cancer: correlation with clinical parameters and
prognosis. J Korean Med Sci 2007;22:318–325.
20. Tzankov A, Went P, Zimpfer A, et al. Tissue microarray technology:
principles, pitfalls and perspectives—lessons learned from hematologi-
cal malignancies. Exp Gerontol 2005;40:737–744.
21. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators
of G1-phase progression. Genes Dev 1999;13:1501–1512.
22. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent
degradation of the cyclin-dependent kinase inhibitor p27 in aggressive
colorectal carcinomas. Nat Med 1997;3:231–234.
23. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the
Journal of Thoracic Oncology • Volume 5, Number 9, September 2010 Deregulation of p27 and Cyclin D1/D3
Copyright © 2010 by the International Association for the Study of Lung Cancer 1335
cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary
breast cancer. Nat Med 1997;3:227–230.
24. Lloyd RV, Erickson LA, Jin L, et al. p27kip1: a multifunctional
cyclin-dependent kinase inhibitor with prognostic significance in human
cancers. Am J Pathol 1999;154:313–323.
25. Singhal S, Vachani A, Antin-Ozerkis D, et al. Prognostic implications of
cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung
cancer: a review. Clin Cancer Res 2005;11:3974–3986.
26. Qi CF, Xiang S, Shin MS, et al. Expression of the cyclin-dependent
kinase inhibitor p27 and its deregulation in mouse B cell lymphomas.
Leuk Res 2006;30:153–163.
27. Sa´nchez-Beato M, Camacho FI, Martínez-Montero JC, et al. Anomalous
high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is
associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocal-
ization in tumor cells. Blood 1999;94:765–772.
28. Ishikawa M, Fujii T, Masumoto N, et al. Correlation of p16INK4A
overexpression with human papillomavirus infection in cervical adeno-
carcinomas. Int J Gynecol Pathol 2003;22:378–385.
29. Volgareva G, Zavalishina L, Andreeva Y, et al. Protein p16 as a marker
of dysplastic and neoplastic alterations in cervical epithelial cells. BMC
Cancer 2004;4:58.
30. Yildiz IZ, Usubu¨tu¨n A, Firat P, et al. Efficiency of immunohistochemical
p16 expression and HPV typing in cervical squamous intraepithelial
lesion grading and review of the p16 literature. Pathol Res Pract
2007;203:445–449.
31. Lipponen P, Saarelainen E, Ji H, et al. Expression of E-cadherin (E-CD)
as related to other prognostic factors and survival in breast cancer.
J Pathol 1994;174:101–109.
32. Elzagheid A, Kuopio T, Ilmen M, et al. Prognostication of invasive
ductal breast cancer by quantification of E-cadherin immunostaining: the
methodology and clinical relevance. Histopathology 2002;41:127–133.
33. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary
carcinomas of the breast and its distant metastases. Breast Cancer Res
2003;5:R217–R222.
34. Liu LK, Jiang XY, Zhou XX, et al. Upregulation of vimentin and
aberrant expression of E-cadherin/beta-catenin complex in oral squa-
mous cell carcinomas: correlation with the clinicopathological features
and patient outcome. Mod Pathol 2010;23:213–224.
35. Lazrˇ D, Tbˇan S, Ardeleanu C, et al. The immunohistochemical expression
of E-cadherin in gastric cancer: correlations with clinicopathological factors
and patients’ survival. Rom J Morphol Embryol 2008;49:459–467.
36. Xu HT, Li QC, Zhang YX, et al. Connexin 43 recruits E-cadherin
expression and inhibits the malignant behaviour of lung cancer cells.
Folia Histochem Cytobiol 2008;46:315–321.
37. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor
overexpression correlates with a poor prognosis in completely resected
non-small-cell lung cancer. Ann Oncol 2004;15:28–32.
38. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth
factor receptor in non-small-cell lung carcinomas: correlation between
gene copy number and protein expression and impact on prognosis.
J Clin Oncol 2003;21:3798–3807.
39. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features
associated with epidermal growth factor receptor gene mutations in lung
cancers. J Natl Cancer Inst 2005;97:339–346.
40. Gautschi O, Ratschiller D, Gugger M, et al. Cyclin D1 in non-small cell
lung cancer: a key driver of malignant transformation. Lung Cancer
2007;55:1–14.
41. Marchetti A, Doglioni C, Barbareschi M, et al. Cyclin D1 and retino-
blastoma susceptibility gene alterations in non-small cell lung cancer. Int
J Cancer 1998;75:187–192.
42. Betticher DC, Heighway J, Hasleton PS, et al. Prognostic significance of
CCND1 (cyclin D1) overexpression in primary resected non-small-cell
lung cancer. Br J Cancer 1996;73:294–300.
43. Jiang W, Kahn SM, Tomita N, et al. Amplification and expression of the
human cyclin D gene in esophageal cancer. Cancer Res 1992;52:2980–
2983.
44. Gillett C, Fantl V, Smith R, et al. Amplification and overexpression of
cyclin D1 in breast cancer detected by immunohistochemical staining.
Cancer Res 1994;54:1812–1817.
45. Kobayashi S, Shimamura T, Monti S, et al. Transcriptional profiling
identifies cyclin D1 as a critical downstream effector of mutant epider-
mal growth factor receptor signaling. Cancer Res 2006;66:11389–
11398.
Sterlacci et al. Journal of Thoracic Oncology • Volume 5, Number 9, September 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1336
